The negative outlook reflects the company's elevated leverage and potential for a downgrade if credit measures do not improve over the next 12 months. A resurgence in COVID-19 cases could prompt renewed economic shutdowns or delayed reopenings, and the demand for some label types could retrench. MCC's pro forma adjusted–debt-to-EBITDA ratio as of March 31, 2020, was very high, roughly 9x. This includes $44 million in transaction costs incurred in September 2019. However, adjusting for the roll-off of those costs and contemplating anticipated cost savings and operational synergies, we see leverage improving to 7.6x by Dec. 31, 2020. Although we expect various sales and operational improvements to support credit measures over the next 12 months, operational execution risks could inhibit